Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 20/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25723619 | 0.93 | CHRM5 (0.81) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456583 | 0.90 | CHRM5 (0.87) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456338 | 0.90 | CHRM5 (0.67) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456632 | 0.89 | CHRM5 (0.71) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25226642 | 0.83 | CHRM5 (1.00) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456916 | 0.83 | CHRM5 (0.87) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25723622 | 0.83 | CHRM5 (0.73) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25723557 | 0.82 | CHRM5 (0.81) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456734 | 0.81 | CHRM5 (0.87) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25276374 | 0.80 | CHRM5 (0.83) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | CHRM5 1/4885CYP3A4 520/4885CYP2D6 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.